title: Topical valrubicin application reduces skin inflammation in murine models.
abstract: BACKGROUND
  Valrubicin is a cytostatic anthracycline analogue, lacking toxicity by skin and tissue contact, and represents a new drug with potential for topical treatment of psoriasis and nonmelanoma skin cancer (NMSC); the beneficial effects have been partly explained by its antiproliferative and proapoptotic characteristics.
  
  
  OBJECTIVE
  To assess the effect of valrubicin on skin inflammation as inflammation also plays a key role in psoriasis and NMSC.
  
  
  METHODS
  The effect of topical valrubicin treatment on skin inflammation in vivo was addressed in skin inflammation mouse models, where 12-O-tetradecanoylphorbol 13-acetate was used to induce irritant contact dermatitis. An acute and a chronic model were included, to investigate the effect of valrubicin in short-term inflammation and in more persistent inflammation. Inflammation-associated ear oedema was evaluated by measuring ear thickness, infiltration of neutrophil cells, and expression of inflammatory cytokines, interleukin (IL)-1β and IL-6.
  
  
  RESULTS
  Topical valrubicin treatment effectively reduced the inflammatory response in the acute and the chronic models.
  
  
  CONCLUSIONS
  The present data document an anti-inflammatory effect of valrubicin, and may suggest an interesting new role for valrubicin in other debilitating skin diseases in which inflammation is a significant factor.
authors.affiliation: Department of Dermatology, Aarhus University Hospital, DK-8000 Aarhus C, Denmark.
authors.forename: E
authors.initials: E
authors.lastname: Hauge
authors.forename: H
authors.initials: H
authors.lastname: Christiansen
authors.forename: C
authors.initials: C
authors.lastname: Rosada
authors.forename: E
authors.initials: E
authors.lastname: de Darkó
authors.forename: T N
authors.initials: TN
authors.lastname: Dam
authors.forename: K
authors.initials: K
authors.lastname: Stenderup
mesh_terms: D000208:Acute Disease; D000279:Administration, Cutaneous; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000494:pharmacology; D002908:Chronic Disease; D016207:Cytokines / Q000378:metabolism; D017453:Dermatitis, Irritant / Q000188:drug therapy*; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D007509:Irritants / Q000633:toxicity; D051379:Mice; D008810:Mice, Inbred C57BL; D020556:Neutrophil Infiltration; D013755:Tetradecanoylphorbol Acetate / Q000031:analogs & derivatives / Q000633:toxicity
chemical_list: C554292:12-O-tetradecanoylphorbol-1,3-acetate; D000893:Anti-Inflammatory Agents; D016207:Cytokines; D007509:Irritants; C016163:valrubicin; D004317:Doxorubicin; D013755:Tetradecanoylphorbol Acetate